Home › Prostate Cancer › New York › The Bronx
Prostate Cancer clinical trials in The Bronx, NY
12 studies for Prostate Cancer are looking for participants at sites in and around The Bronx (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RecruitingPhase 3
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center-Weiler Hospital, The Bronx
- Montefiore Medical Center - Moses Campus, The Bronx
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
RecruitingPhase 1
- Montefiore Medical Center, The Bronx
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
RecruitingPhase 3
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center - Moses Campus, The Bronx
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RecruitingPhase 1
- Montefiore Medical Center, The Bronx
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
RecruitingPhase 2
- James J. Peters VA Medical Center, Bronx, NY, The Bronx
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
RecruitingPhase 3
- Montefiore Medical Center, The Bronx
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
RecruitingPhase 3
- Montefiore Einstein Comprehensive Cancer Center, The Bronx
- Montefiore Medical Center- Montefiore Medical Park, The Bronx
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
RecruitingPhase 3
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center - Moses Campus, The Bronx
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
RecruitingPhase 2/3
- Montefiore Medical Center, The Bronx
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
RecruitingPhase 3
- Montefiore Medical Center-Einstein Campus, The Bronx
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
RecruitingPhase 2
- James J. Peters VA Medical Center, The Bronx
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
RecruitingPhase 4
- Montefiore Medical Center, The Bronx
About Prostate Cancer
Prostate cancer is one of the most common types of cancer among American men. The risk goes up as men age. Learn about symptoms, tests, and treatment.
More about Prostate Cancer on MedlinePlus
Prostate Cancer trials in other cities
- New York City, NY101 studies
- Houston, TX73 studies
- Los Angeles, CA64 studies
- Boston, MA56 studies
- Seattle, WA45 studies
- St. Louis, MO45 studies
- Chicago, IL45 studies
- Baltimore, MD45 studies
- San Francisco, CA44 studies
- Philadelphia, PA41 studies
- Nashville, TN40 studies
- Washington, DC39 studies
Other studies in The Bronx
- Non-Small Cell Lung Cancer23 studies
- Breast Cancer18 studies
- Acute Myeloid Leukemia15 studies
- Lung Cancer12 studies
- Cardiovascular Disease11 studies
- Cancer (all types)10 studies
- Asthma10 studies
- Heart Failure10 studies
- Head and Neck Squamous Cell Carcinoma9 studies
- Myelodysplastic Syndromes9 studies
- Colorectal Cancer9 studies
- Metastatic Cancer9 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.